SCHEMBL7101641

SCHEMBL7101641

Cc1ccc(Cc2cn(S(=O)(=O)N(C)C)cn2)cc1[N+](=O)[O-]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 6/20 0.37
HTT P42858 2/20 0.37
MCOLN3 Q8TDD5 2/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
KDM4E B2RXH2 2/20 0.35
CYP3A4 P08684 3/20 0.35
TSHR P16473 1/20 0.35
RECQL P46063 1/20 0.35
MAPT P10636 3/20 0.35
CYP1A2 P05177 1/20 0.35
GAA P10253 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7103316 0.78 MAPT (0.39) ALDH1A1HTTKDM4EMAPTGAA
SCHEMBL7166942 0.76 MEN1 (0.38) MEN1KMT2AALDH1A1HTTMCOLN3
SCHEMBL7100988 0.76 CYP1A2 (0.32) MEN1KMT2AALDH1A1HTTMAPT
SCHEMBL3747951 0.75 BACE1 (0.43) CYP1A2CYP2D6SMN1; SMN2NFKB1
SCHEMBL7103392 0.75 NOS3 (0.34) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL22075719 0.74 MEN1 (0.41) MEN1KMT2AALDH1A1HTTKDM4E
SCHEMBL7102328 0.73 CYP19A1 (0.37) ALDH1A1MCOLN3CYP3A4MAPTCYP1A2
SCHEMBL5200630 0.72 MEN1 (0.35) MEN1KMT2AALDH1A1HTTMCOLN3
SCHEMBL17704660 0.72 ALDH1A1 (0.58) MEN1KMT2AALDH1A1HTTMCOLN3
SCHEMBL7842276 0.66 MEN1 (0.52) MEN1KMT2AALDH1A1HTTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ABBOTT LABORATORIES 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ADRA1D, ADRB1, ADRA1A MEN1 3832/4885KMT2A 1672/4885ALDH1A1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.